Sovaprevir, previously referred to as ACH-1625, is an investigational, next-generation NS3/4A protease inhibitor discovered by Achillion. In 2012, Fast Track status was granted by the U.S. Food and Drug Administration (FDA) to sovaprevir for the treatment of chronic hepatitis C viral infection (HCV). Achillion is currently conducting a Phase 2 clinical trial to evaluate the all-oral, interferon-free combination of sovaprevir and the 2nd generation NS5A inhibitor, ACH-3102 , with ribavirin, for a 12 treatment duration, in treatment naïve, genotype 1 (GT1) HCV patients. Future studies will also evaluate this combination of sovaprevir and ACH-3102 without ribavirin for both 8 and 12 week treatment durations. Initial study results are expected during the 2nd half of 2013. Achillion retains worldwide commercial rights to sovaprevir.
• Sovaprevir is a potent next-generation protease inhibitor with activity against all HCV genotypes (GT) including equipotent activity against both GT 1a and 1b (IC50 ~ 1nM)
• With its rapid and extensive partitioning to the liver, as well as high liver/plasma ratios, sovaprevir has been clinically demonstrated to allow for once-daily, non-boosted dosing
• Sovaprevir has been shown to be safe and well tolerated through 12 weeks of treatment in clinical studies to date
• Sovaprevir has demonstrated high rates of clinical cures in combination with pegylated-interferon and RBV in a challenging, real world, patient population of genotype 1 treatment-naive patients and is now being evaluated as part of an all-oral, interferon-free regimen for the treatment of HCV
• Sovaprevir retains activity against mutations that confer resistance to 1st-generation protease inhibitors
• In clinical studies to date, sovaprevir has demonstrated a high pharmacologic barrier to resistance with no on-treatment viral breakthrough reported to date
• Sovaprevir is believed to be synergistic when combined with other classes of DAAs, including the 2nd-generation NS5A inhibitor, ACH-3102
For more information about the next-generation protease inhibitor, sovaprevir, please visit the Data Overview section.
Sovaprevir is an investigational compound. Its safety and efficacy have not been established.